Asset Details
Do you wish to reserve the book?
Drug-Eluting Stents vs. Coronary-Artery Bypass Grafting in Multivessel Coronary Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Drug-Eluting Stents vs. Coronary-Artery Bypass Grafting in Multivessel Coronary Disease
Do you wish to request the book?
Drug-Eluting Stents vs. Coronary-Artery Bypass Grafting in Multivessel Coronary Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Drug-Eluting Stents vs. Coronary-Artery Bypass Grafting in Multivessel Coronary Disease
2008
Overview
In this New York State registry study, outcomes of patients with multivessel coronary disease treated with drug-eluting coronary stents or coronary-artery bypass grafting (CABG) were compared during 18 months of follow-up. The rates of death, death or myocardial infarction, and repeat revascularization were consistently lower after CABG than after treatment with drug-eluting stents.
The rates of death, death or myocardial infarction, and repeat revascularization were consistently lower after CABG than after treatment with drug-eluting stents.
Several studies have compared the long-term outcomes of coronary-artery bypass grafting (CABG) and coronary stenting.
1
–
5
In 2003, drug-eluting stents were introduced for the purpose of reducing restenosis, which has continued to be a problem associated with the use of bare-metal stents. Many randomized, controlled trials have documented lower rates of clinical and angiographic restenosis, target-lesion revascularization, and major adverse cardiac events with drug-eluting stents.
6
–
20
However, recent reports of the danger of late stent thrombosis among patients with drug-eluting stents
21
,
22
led to a meeting of a Food and Drug Administration (FDA) advisory committee that addressed the safety of . . .
Publisher
Massachusetts Medical Society
Subject
/ Angioplasty, Balloon, Coronary
/ Biological and medical sciences
/ Coronary Artery Bypass - adverse effects
/ Coronary Disease - mortality
/ Coronary Restenosis - epidemiology
/ Drug-Eluting Stents - adverse effects
/ Female
/ Heart
/ Humans
/ Male
/ Myocardial Infarction - epidemiology
/ Myocardial Infarction - mortality
/ Myocardial Revascularization - statistics & numerical data
/ Postoperative Complications - epidemiology
/ Postoperative Complications - mortality
/ Stents
/ Surgery
